article thumbnail

Genomics/Biobanks/Cohort Studies

Broad Institute

He has had continuous NIH funding for the past 25 years and was Director of the Academy of Finland Centre of Excellence in Complex Disease Genetics (2007-2011). He has been cited over 100,000 times (WoS 6/2023) and has a H-index of 140 (6/2023). Recent genetic risk scores have been shown to strongly predict CVD-related outcomes (e.g.,

article thumbnail

Bristol Myers Squibb Statement on Istodax® (romidepsin) Relapsed/Refractory Peripheral T-cell Lymphoma U.S. Indication

The Pharma Data

In 2011, Celgene Corporation, now a wholly owned subsidiary of Bristol Myers Squibb, received accelerated approval by the U.S.

Nurses 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

The Pharma Data

Results demonstrated a substantial decrease in the time to diagnosis from >6 years of age (2011-2015) to <2 years of age (2019-2020). Participants continue to receive their usual care, and will be observed by a team of doctors and nurses over time for up to two years. of all patients. About STK-001.

article thumbnail

CheckMate -577, a Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival

The Pharma Data

Because many drugs, including antibodies, are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from OPDIVO or YERVOY, advise women not to breastfeed during treatment and for at least 5 months after the last dose. In 2011, through a collaboration agreement with Ono Pharmaceutical Co.,

article thumbnail

CheckMate -649, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Chemotherapy vs. Chemotherapy, Meets Primary Endpoints Demonstrating Superior Overall Survival and Progression-Free Survival in First-Line Treatment of Gastric and Esophageal Cancers

The Pharma Data

Because many drugs, including antibodies, are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from OPDIVO or YERVOY, advise women not to breastfeed during treatment and for at least 5 months after the last dose. In 2011, through a collaboration agreement with Ono Pharmaceutical Co.,

article thumbnail

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

The Pharma Data

The majority (80% of nurse practitioners, 79% of nephrologists, 73% of endocrinologists, 69% of primary care physicians and 63% of cardiologists) agree they would call another specialist to help treat these patients if they had the resources. The findings are from a survey of 1,000 U.S. healthcare professionals (i.e., Nicholas, M.D.,

Nurses 52
article thumbnail

Unblock My Hormones And Start Burning Fat TODAY With HB5

The Pharma Data

I could hear doctors and nurses speaking in hushed tones…. And Mary-Anne, a nurse from Arkansas, who says…. Meanwhile, a 2011 study from Drexel University found that African Mango: “Is effective in reducing body weight and improving metabolic parameters in overweight humans”…xxxiii. But I was paying attention to any of that.